Deep Learning with Yacine on MSN

Nesterov accelerated gradient (NAG) from scratch in Python – step-by-step tutorial

Dive deep into Nesterov Accelerated Gradient (NAG) and learn how to implement it from scratch in Python. Perfect for ...
Deep Learning with Yacine on MSN

Gradient descent from scratch in Python – step by step tutorial

Learn how gradient descent really works by building it step by step in Python. No libraries, no shortcuts—just pure math and ...
GitHub

Python Learning Roadmap in 30 Days

Welcome to the Python Learning Roadmap in 30 Days! This project is designed to guide you through a structured 30-day journey to learn the Python programming language from scratch and master its ...
IEEE

Recursive Least Squares and Adaptive Kalman Filter-Based State and Parameter Estimation for Series Arc Fault Detection on DC Microgrids

Abstract: In this article, we present a recursive least squares (RLS) and adaptive Kalman filter (AKF)-based state and parameter estimation (SE and PE) for series arc fault (SAF) detection and ...
GitHub

scikit-mobility - mobility analysis in Python

represent trajectories and mobility flows with proper data structures, TrajDataFrame and FlowDataFrame. manage and manipulate mobility data of various formats (call detail records, GPS data, data from ...
IEEE

IEEE Communications Surveys and Tutorials

Abstract: I welcome you to the fourth issue of the IEEE Communications Surveys and Tutorials in 2021. This issue includes 23 papers covering different aspects of communication networks. In particular, ...
stockstelegraph

Recursion Pharmaceuticals, Inc. (RXRX): JP Morgan Upgrades to Overweight with Significant Upside Potential

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...
Seeking Alpha

Recursion jumps as J.P. Morgan upgrades on lead program

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...